BioLife Solutions, Inc
BioLife Solutions Inc. is a U.S.-based life sciences company focused on bioproduction tools and services for the cell and gene therapy industry. It develops, manufactures, and markets products designed to preserve the health and function of biologic material during sourcing, manufacturing, storage, and transport. The company’s portfolio centers on biopreservation media, cell processing products, and automated thawing and handling devices used in research and commercial manufacturing. BioLife has also used acquisitions and divestitures to sharpen its focus on the core bioproduction workflow. Its business model is tied to the growth of commercial cell and gene therapies, where product reliability and handling quality are critical.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueSpecialized media used to maintain viability and function of biologic material during sourcing, processing, storage, and transport.
Tools such as hPL media, cryogenic containers, and fill machines used in cell handling and manufacturing workflows.
ThawSTAR devices and related systems that standardize thawing of biologic materials before use.
Smart shipping containers and cold-chain products used to protect biologic materials in transit.
Application support, customer care, and technical services that help customers implement and use the products.
Customers
BioLife sells primarily to cell and gene therapy developers, biopharma manufacturers, and research organizations that need to preserve biologic material with high reliability. Customers buy its products to reduce process risk, improve yield, and maintain cell viability during manufacturing and distribution. The company also serves commercial therapy customers, which is important because recurring demand tends to rise as therapies move from development into approved and scaled production. A meaningful portion of sales is routed through third-party distributors, which broadens reach into regional markets and smaller accounts. The customer base is specialized and technical, so scientific support and workflow integration are part of the buying decision, not just product price.
Buy biopreservation media and processing tools to protect cells during development, scale-up, and clinical manufacturing.
Purchase recurring consumables and workflow products to support approved therapies and commercial production.
Use the company’s media and handling products for basic and translational research involving biologic materials.
Resell the company’s products in regional markets and help extend commercial reach without direct local infrastructure.
Strategy
BioLife’s strategy is to concentrate on the bioproduction workflow for cell and gene therapy and expand the value of its core product platforms. Management emphasizes organic innovation, partnerships, and acquisitions as ways to broaden the portfolio and deepen customer relationships. The company also uses direct sales plus distributors to scale market access while keeping technical support close to the customer. Recent divestitures indicate a sharper focus on the core biopreservation and cell-processing business rather than a broader collection of adjacent assets. This strategy matters because the company competes on workflow relevance, product reliability, and scientific credibility in a highly specialized market.
The company’s competitive position depends on being embedded in the customer’s biologic manufacturing process.
New products can increase wallet share and improve customer retention in a specialized market.
Adjacencies can extend the platform and add capabilities without building everything internally.
Customers buy based on performance, application fit, and support quality, not just product specs.
Geography
BioLife is headquartered in Bothell, Washington and operates as a U.S.-based company with sales to customers located by geography rather than by manufacturing footprint disclosed in the excerpts. The company’s revenue disclosure references customer location, but the provided excerpts do not include a country-by-country revenue table. Its business is exposed to global biopharma and cell-therapy demand because products are used in international manufacturing and distribution workflows. The use of third-party distributors also suggests a broader international commercial footprint than direct sales alone. Geography matters because biologic materials are time- and temperature-sensitive, so local service, shipping reliability, and regulatory access can affect adoption.
Risks
BioLife faces product-performance and technology-risk exposure because its products are used in sensitive biologic workflows where failures can damage customer outcomes and reputation. Demand is tied to the health of the cell and gene therapy market, so funding cycles, customer inventory destocking, and broader biotech sentiment can affect sales. The company also depends on manufacturing continuity and supply availability, making it vulnerable to disruptions in its own facilities or those of third-party suppliers. Public health crises, staffing shortages, and shipping delays can interrupt operations and customer access, which is especially important for temperature-sensitive products. As a specialized life-sciences supplier, it also faces product liability, recall risk, and the need to retain scientific and technical talent.
- Product reliability and technology acceptanceImpact: HighLikelihood: Medium
Customers rely on the products to preserve biologic material, so defects or doubts about performance can directly reduce sales and trust.
Exposure - Product liability and recall exposureImpact: HighLikelihood: Medium
Failures in products used in biologic manufacturing can create claims, remediation costs, and reputational damage.
Exposure: Manufactured and distributed bioproduction products
- Biotech funding and customer inventory cyclesImpact: High
The company’s demand is linked to cell and gene therapy spending, which can fluctuate with funding conditions and destocking.
Exposure: Commercial and development-stage CGT customers
- Public health crisis disruptionImpact: MediumLikelihood: High
Pandemics or epidemics can affect workforce availability, logistics, and customer access.
Exposure - Manufacturing and supply-chain disruptionImpact: MediumLikelihood: Medium
Facility shutdowns or component shortages can delay shipments and reduce revenue recognition timing.
Exposure: Internal manufacturing and outside manufacturers
- Key personnel retentionImpact: MediumLikelihood: Medium
The business depends on scientific, engineering, and sales expertise to support customers and develop products.
Exposure
Accounting
Judgemental itemsThe company sells products and services with different delivery and performance obligations, so timing of recognition can materially affect reported revenue.
Impact: Quarterly and annual revenue comparability
Recent divestitures require separate presentation and can distort trend analysis if not adjusted for.
Impact: Reported revenue, operating income, and cash flow presentation
Acquisitions such as PanTHERA can create identifiable intangibles and potential impairment risk.
Impact: Amortization expense and future impairment charges
Investment balances are marked to market, affecting other comprehensive income and liquidity analysis.
Impact: Balance sheet and equity volatility
Similar listed companies
Publicly listed companies with a comparable business focus.
Cryoport, Inc.
CYRX · Pharmaceutical Preparations
BioRestorative Therapies, Inc.
BRTX · Services-Misc Health & Allied Services, NEC
Repligen Corporation
RGEN · Biological Products, (No Diagnostic Substances)
BioScience Health Innovations, Inc.
BHIC · Services-Computer Processing & Data Preparation
Standard BioTools Inc
LAB · Pharmaceutical Preparations
Impact BioMedical, Inc
IBO · Pharmaceutical Preparations
Last updated: 24/09/2026